<DOC>
	<DOCNO>NCT02944552</DOCNO>
	<brief_summary>The test adopt superiority design multi center , randomize , double-blind , positive control drug , dose finding , use two simulation skill . The qualified subject , accord ratio 1:1:1 , randomize low dose group high dose group positive drug control group , receive treatment course 8 week , individual follow 4 week drug withdrawal .</brief_summary>
	<brief_title>A Multicenter , Randomized , Double-blind Clinical Trial Was Conducted Evaluate Efficacy Safety Bicyclol Treatment Acute Drug-induced Liver Injury Screen Biomarkers Prognosis</brief_title>
	<detailed_description />
	<mesh_term>Drug-Induced Liver Injury</mesh_term>
	<mesh_term>Polyene phosphatidylcholine</mesh_term>
	<criteria>1 . 18~70 year old , male female 2 . The clinical diagnosis acute druginduced liver injury standard : evaluation RUCAM causality scale score equal 6 point . If evaluation RUCAM causality scale score 3~5 , DILI patient need three liver disease expert confirm , opinion three liver specialist consensus 3 . The serum ALT 3and 8 time ULN , TBiL le equal 2 time ULN 4 . Liver biochemical abnormality last less 90 day 5 . Patients understand know nature experiment , nature disease , characteristic drug , relate treatment method risk may need bear participate test , sign inform consent . 1 . Other reason cause liver damage , viral hepatitis , alcoholic liver disease , nonalcoholic fatty liver disease autoimmune liver disease . 2 . Acute liver failure liver function decompensation patient perform , hepatic encephalopathy , ascites , albumin less equal 35g / L , prothrombin time compare normal control extend 3 second . 3 . Serum creatinine great upper limit normal value 1.5 time . 4 . Serious heart , lung , brain , kidney , gastrointestinal systemic disease . 5 . At time take drug affect observation curative effect experiment . 6 . The drug allergy intolerance 7 . With ability express complaint , mental illness severe neurosis patient . 8 . The patient cooperate poor compliance . 9 . Pregnant lactate woman woman prepare pregnancy 10 . The patient participate clinical trial 3 month enter group , within 1 week application hepatoprotective . 11 . The researcher believe suitable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>